We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+9.75%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
-$1.28M
(-0.95%)
Cap. Flow
-$11.4M
Cap. Flow
% of AUM
-8.5%
Top 10 Holdings %
Top 10 Hldgs %
21.49%
Holding
245
New
28
Increased
29
Reduced
140
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$2.85M |
| 2 |
Alphatec Holdings
ATEC
|
+$2.84M |
| 3 |
Indivior Pharmaceuticals
INDV
|
+$2.84M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$2.12M |
| 5 |
APLS
Apellis Pharmaceuticals
APLS
|
+$1.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$4.17M |
| 2 |
Pacira BioSciences
PCRX
|
+$3.36M |
| 3 |
Pfizer
PFE
|
+$3.06M |
| 4 |
United Therapeutics
UTHR
|
+$2.79M |
| 5 |
uniQure
QURE
|
+$2.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.92% |
| 2 | Real Estate | 14.45% |
| 3 | Financials | 7.05% |
| 4 | Industrials | 3.2% |
| 5 | Technology | 2.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Cadence Design Systems
CDNS
$91B
| $339K | 0.25% |
+1,250
| New | +$346K |
|
102
Vera Therapeutics
VERA
$2.76B
| $332K | 0.25% |
+7,500
| New | +$285K |
|
103
Jasper Therapeutics
JSPR
$24.8M
| $329K | 0.24% |
+17,500
| New | +$348K |
|
|
SAFE
104
Safehold
SAFE
$1.22B
| $314K | 0.23% |
11,972
| – | – |
|
105
Synchrony
SYF
$24.8B
| $311K | 0.23% |
6,243
-192
| -3% | -$9.29K |
|
106
Nuvation Bio
NUVB
$2.02B
| $309K | 0.23% |
135,000
| – | – |
|
107
United Airlines
UAL
$37.5B
| $297K | 0.22% |
5,213
-189
| -3% | -$8.75K |
|
108
Gilead Sciences
GILD
$167B
| $293K | 0.22% |
3,500
| – | – |
|
109
Kiniksa Pharmaceuticals
KNSA
$4.92B
| $287K | 0.21% |
+11,478
| New | +$280K |
|
110
Immatics
IMTX
$1.31B
| $285K | 0.21% |
25,000
+5,000
| +25% | +$59.2K |
|
111
DexCom
DXCM
$29.6B
| $280K | 0.21% |
+4,171
| New | +$343K |
|
112
PACCAR
PCAR
$66.4B
| $273K | 0.2% |
2,769
-88
| -3% | -$8.6K |
|
113
Everest Group
EG
$15.1B
| $249K | 0.19% |
636
-23
| -3% | -$8.76K |
|
114
Kinross Gold
KGC
$27B
| $245K | 0.18% |
26,181
-647
| -2% | -$5.81K |
|
115
iShares US & Intl High Yield Corp Bond ETF
GHYG
$185M
| $243K | 0.18% |
5,312
-58
| -1% | -$2.6K |
|
116
FlexShares High Yield Value-Scored Bond Index Fund
HYGV
$1.1B
| $243K | 0.18% |
5,827
-16
| -0.3% | -$655 |
|
117
State Street SPDR Bloomberg High Yield Bond ETF
JNK
$7.36B
| $243K | 0.18% |
2,482
-22
| -0.9% | -$2.11K |
|
118
iShares 0-5 Year High Yield Corporate Bond ETF
SHYG
$7.61B
| $242K | 0.18% |
5,583
-16
| -0.3% | -$684 |
|
119
iShares Fallen Angels USD Bond ETF
FALN
$1.64B
| $242K | 0.18% |
8,857
-79
| -0.9% | -$2.12K |
|
120
Pultegroup
PHM
$24B
| $240K | 0.18% |
1,670
-63
| -4% | -$8.01K |
|
121
Tenet Healthcare
THC
$16.8B
| $237K | 0.18% |
1,426
-40
| -3% | -$6.05K |
|
122
DaVita
DVA
$15.2B
| $229K | 0.17% |
1,396
-55
| -4% | -$8.13K |
|
|
CIM
123
Chimera Investment
CIM
$1.08B
| $222K | 0.17% |
14,022
-1
| -0% | -$15 |
|
124
Viking Therapeutics
VKTX
$4.31B
| $222K | 0.16% |
3,500
-13,000
| -79% | -$763K |
|
125
Cintas
CTAS
$81.8B
| $208K | 0.15% |
1,012
-72
| -7% | -$13.9K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, AlphaCentric Advisors held 245 positions worth $135M, down 0.95% from $136M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
AlphaCentric Advisors withdrew a net $11.4M in Q3 2024, closing 15 positions and reducing 140 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $4.17M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 60% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Merck worth $2.73M.
- AlphaCentric Advisors's largest Q3 2024 buy was Merck: 24,000 shares worth $2.73M.
- AlphaCentric Advisors added most to Neurocrine Biosciences in Q3 2024, an estimated $2.12M increase.
- AlphaCentric Advisors's biggest Q3 2024 reduction was Pfizer, cutting an estimated $3.06M.
- AlphaCentric Advisors fully exited BioCryst Pharmaceuticals in Q3 2024, selling an estimated $4.17M.
- AlphaCentric Advisors's ten largest holdings make up 21% of its $135M portfolio in Q3 2024.
- AlphaCentric Advisors opened 28 new positions and closed 15 in Q3 2024.
- AlphaCentric Advisors's portfolio value fell 0.95% quarter-over-quarter to $135M.
Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.